AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Photocure ASA

Transaction in Own Shares Sep 1, 2021

3714_rns_2021-09-01_3b47f052-21ca-4fef-b247-43574a884e57.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

Photocure ASA: Update on holding of own shares

Photocure ASA: Update on holding of own shares

Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release

by Photocure ASA ("Photocure" or the "Company") published on 31 August 2021

regarding exercise of share options and sale of own shares, together with

primary insider notifications.

The sale of 7,126 option shares has been completed as previously announced.

Following the transaction Photocure will hold 13,884 own shares.

For further information, please contact:

Photocure

CFO Erik Dahl

Tel: +47 450 55 000

Email: [email protected]

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject to the disclosure requirements set out in section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.